BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

OrbusNeich Files Patent Infringement Actions Against Boston Scientific Corporation (BSX) in Germany and the Netherlands


2/20/2013 10:06:19 AM

FORT LAUDERDALE, Fla., Feb. 20, 2013 /PRNewswire/ -- OrbusNeich today announced that OrbusNeich Medical GmbH and Orbus International B.V., subsidiaries of OrbusNeich Medical, Inc., (collectively, "OrbusNeich") have commenced patent infringement actions in Germany and The Netherlands against Boston Scientific Corporation (NYSE: BSX) ("Boston Scientific") and its distribution affiliates in those countries.

The Complaints allege that Boston Scientific infringed two European patents covering certain novel stent designs. The two patents, held by OrbusNeich, are designated EP 2 311 412 and EP 1 341 482. OrbusNeich alleges that these patents are infringed by several of Boston Scientific's coronary stent systems, including the "PROMUS Element", "PROMUS Element Plus", "OMEGA PtCr", and "TAXUS Element" lines of stents.

OrbusNeich is seeking, among other things, a preliminary injunction prohibiting Boston Scientific from marketing and selling the infringing stents in Germany and The Netherlands. OrbusNeich also seeks damages for all sales of infringing products and a recall of commercially distributed, but not yet used stents in the Netherlands and to seize commercially distributed, but not yet used stents that are still in the possession of Boston Scientific in Germany.

"We will take all necessary actions to protect OrbusNeich from unlawful competitive practices," said Al Novak, Chairman and Chief Executive Officer of OrbusNeich. "Through these proceedings, we are seeking to safeguard these technologies for the benefit of our physician customers and their patients as well as our investors and employees."

On February 11, 2013, OrbusNeich received a favorable ruling from the European Patent Office (EPO) in connection with EP 1 341 482, one of the two patents asserted against Boston Scientific in these lawsuits. The EPO upheld the validity of claim 1 of the '482 patent, as amended, over an opposition filed by Boston Scientific and Terumo Kabushiki Kaisha. The EPO found that claim 1 of the '482 patent met all requirements of the European Patent Convention, and that the stents covered by the claim were novel and inventive over the prior art.

A patent infringement action was also filed by OrbusNeich in the United States in 2009. That suit has currently been stayed pending review of the patents under re-examination procedures in the United States Patent and Trademark Office. The Company notes that it is also reviewing its options with respect to this litigation.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule, R stent, Scoreflex, Sapphire, Sapphire II and Sapphire NC. Development stage products include the COMBO Dual Therapy Stent, the world's first dual therapy stent. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and its innovative technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.

Global Media Contacts:

Dan Katcher / Jamie Moser
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

SOURCE OrbusNeich



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES